Atreca

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.

SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2022 and provided an overview of recent developments.

Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer.

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets

Atreca Announces Corporate Reorganization to Extend Cash Runway

SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2022 and provided an overview of recent developments.

Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the peer-reviewed publication of preclinical data demonstrating how its lead product candidate, ATRC-101, activates the immune system and drives tumor destruction in a Proceedings of the National Academy of Sciences (PNAS) paper titled “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101.”

Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”

Preliminary evidence shows that ATRC-101 helps those patients with higher target expression; 8 out of 12 patients (66%) who took ATCR-101 with H-score ≥ 50 responded. Phase 1b study was updated to recruit higher expression solid tumor patients for ATRC-101, with additional monotherapy and combination data expected in 2nd half of 2022.

Atreca: Biotech With Promise Based On First Candidate ATRC-101

SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that management will present at the following upcoming virtual investor conferences:

Atreca to Present at Upcoming Virtual Investor Conferences

Atreca Announces Licensing Agreement with Zymeworks

Atreca Announces Expansion of Preclinical Pipeline

SAN CARLOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will host a virtual R&D Day on Tuesday, April 5, 2022, at 4:15 p.m. EDT, focused on the Company's preclinical pipeline programs in oncology.

Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022

Here is how Atreca, Inc. (BCEL) and Indivior PLC (INVVY) have performed compared to their sector so far this year.

Has Atreca, Inc. (BCEL) Outpaced Other Medical Stocks This Year?

The consensus price target hints at a 310.2% upside potential for Atreca, Inc. (BCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Atreca, Inc. (BCEL) Climb 310% to Reach the Level Wall Street Analysts Expect?

Camber Energy

Gran Tierra Energy

Are these penny stocks on your watch list for this week? The post Best Penny Stocks to Watch This Week?

Best Penny Stocks to Watch This Week? 3 For Your Watch List

Atreca, Inc. (BCEL) CEO John Orwin on Q4 2021 Results - Earnings Call Transcript

SAN CARLOS, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John Orwin, President and CEO, will participate in a panel discussion at Cowen's 42nd Annual Healthcare Conference, being held virtually March 7-9, 2022.

Atreca to Participate in Cowen 42nd Annual Healthcare Conference

Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial

Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update

SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will report fourth quarter 2021 financial results and members of the company's management team will host a year-end conference call, which will include an update on progress in the ongoing ATRC-101 clinical program, on Thursday, March 3, 2022, at 4:30 p.m. EST.

Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Atreca, Inc. (BCEL) Upgraded to Buy: Here's What You Should Know

Atreca's share price performance has been abysmal over the past 12 months - the stock has lost >85% of its value. The biotech IPOd in June 2019, raising >$100m to fund development of drugs developed by studying the successful immune responses of patients.

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present data on broadly neutralizing SARS-CoV-2 antibodies discovered by the company at the upcoming Keystone Symposia Conference: Antibodies as Drugs, being held January 30 – February 2, 2022 both in Keystone, Colo. and virtually.

Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

Atreca announced preliminary results using ATRC-101 in a phase 1b study treating patients with advanced solid tumors. One expansion cohort will include the combination of ATRC-101 and Keytruda which already began, the 2nd expansion cohort is expected to start Q4 2021 which includes ATRC-101 and chemotherapy.

Atreca Is A Unique Biotech With Key Data Readouts In Coming Years

SAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent developments.

Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Atreca Inc (NASDAQ: BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 to prevent malaria.  MAM01/ATRC-501 is a monoclonal antibody entering preclinical development.

Atreca Ink Licensing Pact With Gates Research On Malaria Antibody

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2021 Annual Meeting, which is being held November 10-14, 2021 in Washington, D.C.

Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

BCEL has very high smart money involvement. Poor adverse event data brought the stock down in July.

News for Atreca Stock (BCEL)